MINIPRESS XL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINIPRESS XL (MINIPRESS XL).
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and reduces peripheral vascular resistance via blockade of postsynaptic alpha-1 receptors on vascular smooth muscle.
| Metabolism | Primarily hepatic via cytochrome P450 enzymes, including CYP3A4 and CYP2D6 pathways. |
| Excretion | Renal (primarily as metabolites, ~90% in urine, <10% unchanged), biliary/fecal (~10%) |
| Half-life | 2–3 hours in normotensive patients; prolonged to 6–10 hours in hypertension; extended by renal impairment (up to 4–6 hours in creatinine clearance <10 mL/min) |
| Protein binding | 97% bound to plasma proteins (predominantly albumin and alpha-1-acid glycoprotein) |
| Volume of Distribution | 0.5–0.8 L/kg (excluding free fraction); lower in heart failure (0.3–0.5 L/kg) due to compartmental shifts |
| Bioavailability | 50–60% (first-pass metabolism significantly reduces oral bioavailability; food delays absorption but reduces peak concentration variability) |
| Onset of Action | Oral: 30–90 minutes for first-dose effect; peak 2–4 hours for sustained antihypertensive effect |
| Duration of Action | 24 hours after single dose (sustained release); 10–12 hours for immediate release; clinical duration may extend beyond half-life due to prolonged receptor binding |
| Action Class | Adrenergic receptor (alpha) antagonist- selective |
| Brand Substitutes | DavaIndia Prazosin 5mg Tablet, Prozoten 5mg Tablet, Resplend 5mg Tablet, Prazowin 5mg Tablet, Prazotag 5mg Tablet |
Initial: 1 mg orally once daily at bedtime, gradually increased to 2-20 mg/day in divided doses.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific dosage adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, reduce dose by 50%; for GFR <10 mL/min, reduce dose by 75%. |
| Liver impairment | Child-Pugh Class A: reduce initial dose to 0.5 mg daily; Class B: 0.25 mg daily; Class C: contraindicated. |
| Pediatric use | Hypertension: Initial 0.05-0.1 mg/kg/day orally in 3 divided doses, max 0.5 mg/kg/day. |
| Geriatric use | Initial dose 0.5 mg orally at bedtime; titrate cautiously; monitor for orthostatic hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINIPRESS XL (MINIPRESS XL).
| Breastfeeding | Prazosin is excreted into human breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.1. Based on limited data, estimated infant dose is <1% of maternal weight-adjusted dose, unlikely to cause adverse effects. Use with caution in lactating women, especially with premature or low-birth-weight infants, and monitor for signs of hypotension or sedation. |
| Teratogenic Risk | Prazosin is classified as FDA Pregnancy Category C. Animal studies have shown fetal resorption and reduced fetal survival at doses 12 times the maximum human dose. There are no adequate well-controlled studies in pregnant women. First trimester: theoretical risk of teratogenicity; avoid unless benefit outweighs risk. Second/third trimester: may cause maternal hypotension, reduced uteroplacental perfusion, and fetal hypoxia. Use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to prazosin or any component of the formulation"]
| Precautions | ["Orthostatic hypotension, especially with first dose ('first-dose syncope')","Risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery","Sodium restriction recommended in hypertensive patients","Caution in patients with hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure monitoring at each visit; heart rate; signs of orthostatic hypotension; renal function and electrolytes periodically. Fetal: Ultrasound monitoring for growth restriction if used in third trimester; non-stress test or biophysical profile as clinically indicated for maternal hypotension. |
| Fertility Effects | No specific human data on fertility effects. Animal studies: prazosin did not impair fertility in rats at doses up to 75 mg/kg/day (approximately 20 times human dose). In males, prazosin can cause priapism (rare) and may affect erectile function; no data on sperm parameters. In females, no known impact on ovulation or conception. Consider potential for reduced libido or ejaculatory dysfunction in men. |